Pages

Sunday, June 1, 2014

Seattle Genetics Presents Data from Phase 1 Clinical Trial of...

'We continue to make strong progress advancing our proprietary pipeline programs, with SGN-CD19A representing one of five ADCs in clinical development.

http://ift.tt/1gTCYq3

No comments:

Post a Comment